AMAG PHARMACEUTICALS, INC. — Revenue by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1239f554-c7a9-4bab-b455-bfbbae405a72/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2019 | $326.5M | 2019-01-01 – 2019-12-31 | evidence 0000792977-20-000090 |
| FY 2018 | $472.0M | 2018-01-01 – 2018-12-31 | evidence 0000792977-20-000090 |
| FY 2017 | $494.0M | 2017-01-01 – 2017-12-31 | evidence 0000792977-20-000090 |
| FY 2016 | $432.5M | 2016-01-01 – 2016-12-31 | evidence 0000792977-19-000036 |
| FY 2015 | $418.3M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-003420 |
| FY 2014 | $124.4M | 2014-01-01 – 2014-12-31 | evidence 0001047469-15-000871 |
| FY 2013 | $80.9M | 2013-01-01 – 2013-12-31 | evidence 0001047469-14-000718 |
| FY 2012 | $85.4M | 2012-01-01 – 2012-12-31 | evidence 0001047469-13-002092 |
| FY 2011 | $61.2M | 2011-01-01 – 2011-12-31 | evidence 0001047469-12-002297 |
| FY 2010 | $66.2M | 2010-01-01 – 2010-12-31 | evidence 0001047469-11-001351 |
| FY 2009 | $17.2M | 2009-01-01 – 2009-12-31 | evidence 0001047469-11-001351 |
| FY 2008 | $1.9M | 2008-01-01 – 2008-12-31 | evidence 0001047469-11-001351 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
AMAG PHARMACEUTICALS, INC. — all facts · Net Income · Operating Income